To stop the use of Imatinib in CML-CP patients
Not Applicable
- Conditions
- Health Condition 1: - Health Condition 2: C921- Chronic myeloid leukemia, BCR/ABL-positive
- Registration Number
- CTRI/2019/07/020407
- Lead Sponsor
- DR BRA IRCH AIIMS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
a). Age >= 18 years
b). CML-CP on imatinib mesylate
c). Optimal response to imatinib
d). Minimum duration of imatinib mesylate treatment of 3 years
e) At least complete molecular remission MR4
f). Deep molecular remission duration should be at least one year
g) Baseline data and documentation of treatment should be available for outside treated patients
Exclusion Criteria
a) Patients who had CML-accelerated phase/ blast crisis at diagnosis
b) High Sokal score
c). Not willing for the study
d) Pregnancy
e) Female patient not willing to use contraception
f) Patients not willing for regular follow up
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method